MAP3K19

Mitogen-activated protein kinase kinase kinase 19 · Q56UN5 · MAP3K19 on Sugi Atlas →

10,890 patent compounds predicted against MAP3K19, 8,717 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bms-345541 (SCHEMBL118886)	1.00	2/20
SCHEMBL672223	0.62	2/20
SCHEMBL903267	0.53	2/20
SCHEMBL100391	0.50	2/20
SCHEMBL98884	0.48	2/20
SCHEMBL100036	0.47	2/20
SCHEMBL120582	0.39	2/20
Vatalanib (SCHEMBL18286)	1.00	1/20
Motesanib (SCHEMBL187470)	1.00	1/20
Pictilisib (SCHEMBL190812)	1.00	1/20
Pi-103 (SCHEMBL258242)	1.00	1/20
Gsk-461364 (SCHEMBL310080)	1.00	1/20
Tg100-115 (SCHEMBL360279)	1.00	1/20
Tandutinib (SCHEMBL927974)	1.00	1/20
Motesanib (SCHEMBL445079)	0.98	1/20
Vatalanib (SCHEMBL905598)	0.97	1/20
Vatalanib (SCHEMBL905616)	0.97	1/20
SCHEMBL190513	0.95	1/20
Motesanib (SCHEMBL446673)	0.95	1/20
SCHEMBL31205	0.88	1/20

Clinical trials — most relevant to MAP3K19 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Study of ASTX029 in Subjects With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	PHASE2	RECRUITING
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Histiocytic Disorder Follow-up Study	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP3K19 binder may also engage these)

Protein	Name	Similarity
Q7Z570	—	1.000	Q7Z570 →
Q8N9V7	—	1.000	Q8N9V7 →
E9Q3S4	—	1.000	E9Q3S4 →
F6ULY3	—	1.000	F6ULY3 →
Q864U1	—	1.000	Q864U1 →
Q6J6I9	—	0.999	Q6J6I9 →
G3S077	—	0.999	G3S077 →
A0A140LI88	—	0.999	A0A140LI88 →
E1BC15	—	0.998	E1BC15 →
F7DF15	—	0.998	F7DF15 →
A4D1E1	—	0.998	A4D1E1 →
Q0VBV7	—	0.998	Q0VBV7 →
Q6J6J0	—	0.998	Q6J6J0 →
Q2M3C7	—	0.998	Q2M3C7 →
Q5VWN6	—	0.998	Q5VWN6 →
Q9Y2F5	—	0.998	Q9Y2F5 →
Q68DQ2	—	0.997	Q68DQ2 →
O35923	—	0.997	O35923 →
Q8N7Z5	—	0.997	Q8N7Z5 →
Q9P2D6	—	0.997	Q9P2D6 →
Q28DZ0	—	0.997	Q28DZ0 →
Q6NSW3	—	0.997	Q6NSW3 →
E5FYH1	—	0.997	E5FYH1 →
P0C6C0	—	0.997	P0C6C0 →
Q864S8	—	0.996	Q864S8 →
G7NY55	—	0.996	G7NY55 →
Q86XD8	—	0.996	Q86XD8 →
Q8NDH2	—	0.996	Q8NDH2 →
O54952	—	0.996	O54952 →
E5FYH0	—	0.995	E5FYH0 →